These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 31568620)
1. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. Brown A; Welzel TM; Conway B; Negro F; Bräu N; Grebely J; Puoti M; Aghemo A; Kleine H; Pugatch D; Mensa FJ; Chen YJ; Lei Y; Lawitz E; Asselah T Liver Int; 2020 Apr; 40(4):778-786. PubMed ID: 31568620 [TBL] [Abstract][Full Text] [Related]
2. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916 [TBL] [Abstract][Full Text] [Related]
4. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis. Lu M; Rupp LB; Melkonian C; Trudeau S; Daida YG; Schmidt MA; Gordon SC Adv Ther; 2024 Feb; 41(2):744-758. PubMed ID: 38169058 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
6. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689 [TBL] [Abstract][Full Text] [Related]
7. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
8. Tobacco Product Use and Associated Factors Among Middle and High School Students - National Youth Tobacco Survey, United States, 2021. Gentzke AS; Wang TW; Cornelius M; Park-Lee E; Ren C; Sawdey MD; Cullen KA; Loretan C; Jamal A; Homa DM MMWR Surveill Summ; 2022 Mar; 71(5):1-29. PubMed ID: 35271557 [TBL] [Abstract][Full Text] [Related]
9. Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings. Constantin AM; Noertjojo K; Sommer I; Pizarro AB; Persad E; Durao S; Nussbaumer-Streit B; McElvenny DM; Rhodes S; Martin C; Sampson O; Jørgensen KJ; Bruschettini M Cochrane Database Syst Rev; 2024 Apr; 4(4):CD015112. PubMed ID: 38597249 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Reece D; Imrie K; Stevens A; Smith CA; Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013 [TBL] [Abstract][Full Text] [Related]
11. The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol. Walter H; Sadeque-Iqbal F; Ulysse R; Castillo D; Fitzpatrick A; Singleton J JBI Database System Rev Implement Rep; 2015 Oct; 13(10):69-81. PubMed ID: 26571284 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561 [TBL] [Abstract][Full Text] [Related]
13. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis. Shabaninejad H; Kenny RP; Robinson T; Stoniute A; O'Keefe H; Still M; Thornton C; Pearson F; Beyer F; Meader N Health Technol Assess; 2024 Oct; 28(75):1-75. PubMed ID: 39487741 [TBL] [Abstract][Full Text] [Related]
14. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT. Crawley E; Anderson E; Cochrane M; Shirkey BA; Parslow R; Hollingworth W; Mills N; Gaunt D; Treneman-Evans G; Rai M; Macleod J; Kessler D; Pitts K; Cooper S; Loades M; Annaw A; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Metcalfe C Health Technol Assess; 2024 Oct; 28(70):1-134. PubMed ID: 39485730 [TBL] [Abstract][Full Text] [Related]
15. The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review. O'Leary C; Ralphs R; Stevenson J; Smith A; Harrison J; Kiss Z; Armitage H Campbell Syst Rev; 2024 Jun; 20(2):e1396. PubMed ID: 38645303 [TBL] [Abstract][Full Text] [Related]
16. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT. Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608 [TBL] [Abstract][Full Text] [Related]
17. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]